335 related articles for article (PubMed ID: 25684317)
1. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH
Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317
[TBL] [Abstract][Full Text] [Related]
2. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
[TBL] [Abstract][Full Text] [Related]
3. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
4. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
5. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
[TBL] [Abstract][Full Text] [Related]
6. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
7. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
10. Management of Hepatic Encephalopathy: A Primer.
Jawaro T; Yang A; Dixit D; Bridgeman MB
Ann Pharmacother; 2016 Jul; 50(7):569-77. PubMed ID: 27126547
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
Eltawil KM; Laryea M; Peltekian K; Molinari M
World J Gastroenterol; 2012 Feb; 18(8):767-77. PubMed ID: 22371636
[TBL] [Abstract][Full Text] [Related]
12. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
13. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
14. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
15. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Overt Hepatic Encephalopathy.
Sussman NL
Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.
Miglio F; Valpiani D; Rossellini SR; Ferrieri A
Curr Med Res Opin; 1997; 13(10):593-601. PubMed ID: 9327194
[TBL] [Abstract][Full Text] [Related]
18. [Options in the treatment of hepatic encephalopathy].
Petersen KU
Med Monatsschr Pharm; 2015 May; 38(5):160-4. PubMed ID: 26364405
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Cai XJ; Wang L; Hu CM
J Cell Biochem; 2018 Nov; 119(10):8336-8345. PubMed ID: 29932239
[TBL] [Abstract][Full Text] [Related]
20. Review article: the current pharmacological therapies for hepatic encephalopathy.
Bass NM
Aliment Pharmacol Ther; 2007 Feb; 25 Suppl 1():23-31. PubMed ID: 17295849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
